Veloxis Pharmaceuticals: Consulting Fees for Work That Never Happened

In the Veloxis Envarsus kickback settlement, Veloxis Pharmaceuticals agreed to pay $34.45 million to resolve allegations that payments to health care providers and specialty pharmacies caused false claims for its kidney-transplant drug. It also agreed to a separate $1.55 million civil penalty for failing to report physician payments under the Sunshine Act.

The company admitted paying for consulting work that never happened and disguising pharmacy kickbacks as service fees. It also admitted falsifying the expense reports behind its physician-payment disclosures. For someone who knows the contracts, the events or the pharmacy accounts, this case is about the distance between what the company paid for and what its paperwork said it bought.

The Department of Justice announced the civil settlement on August 10, 2026. The government alleged that the resulting Envarsus prescriptions generated claims to Medicare, Medicaid and TRICARE.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by paying people who can influence prescriptions or purchases to favor the manufacturer’s drug. In the Envarsus case, the payments reached both transplant healthcare providers and the specialty pharmacies buying the medicine.

Veloxis, based in Cary, North Carolina, manufactured and sold Envarsus XR, a once-daily immunosuppressant for adult kidney-transplant recipients. It was the company’s only drug at the time. Envarsus competed against a cheaper generic. Winning a place in transplant care meant winning business for the product on which the company depended.

The government’s account describes a marketing effort aimed at people connected to transplant centers and hospitals who could influence the facility’s formulary or treatment protocol. A prescriber could choose the drug for a patient. Someone influencing the hospital’s drug list or protocol could help establish its place in the facility’s treatment decisions.

The admitted payments bought an advantage over cheaper competition, while taxpayers funded the prescriptions the government alleged were tainted by kickbacks.

Consulting Agreements Without the Consulting

Veloxis admitted that it paid kickbacks to healthcare providers from 2016 to 2023 through lavish meals, alcohol, expensive trips, resort stays, gifts and purported consulting fees. The civil settlement admissions also describe agreements for consulting work that was never performed.

The advisory-board arrangements supplied a business explanation for expensive hospitality. The Department of Justice describes trips and retreats under that label, sometimes involving providers’ spouses or guests. A trip could appear to be a professional engagement. A payment could appear to compensate advice. The company admitted that the purpose was to induce Envarsus prescriptions.

In Veloxis’s civil admissions, the paperwork existed while the consulting work did not.

This is why an insider’s account can reach further than a payment total. Someone involved in arranging the event or paying the consultant may know whether the services described on paper ever happened.

Pharmacy Payments Kept Coming Without the Promised Services

Veloxis admitted paying specialty-pharmacy kickbacks from 2017 to 2023 on a per-patient and per-month basis. The purpose was to induce pharmacies to begin or continue purchasing Envarsus instead of competing drugs, including a cheaper generic.

The written contracts described the payments as compensation for “enhanced services” such as data collection or adherence services. Those descriptions gave the payments a service-based explanation, but Veloxis admitted paying pharmacies regardless of whether they supplied data at all, supplied the specified fields or used the specified format. It also admitted paying without confirming that adherence services had been provided.

By Veloxis’s own admission, payment continued despite those failures. The pharmacy’s purchase of Envarsus was the commercial objective behind the service description.

The provider and pharmacy arrangements operated at different points in the same business. One sought influence over prescribing and drug selection. The other paid the purchaser to keep buying. In both, the company admitted using a description of professional services to disguise a payment for drug business.

Another Kidney-Transplant Drug, Another Pharmacy Incentive

Novartis’s 2015 specialty-pharmacy settlement included allegations that it offered rebates to pharmacies in return for recommending that doctors switch patients to Myfortic, another anti-rejection drug for kidney-transplant recipients. The government’s complaint made the alleged exchange explicit:

The parallel is the pharmacy’s influence over product choice. Novartis allegedly bought recommendations to switch drugs. Veloxis admitted using service contracts to induce purchases of its drug. An employee who knows the pharmacy relationship may understand what the manufacturer expected in return for the money, even when the contract describes something else.

Veloxis Envarsus False Expense Reports and the Sunshine Penalty

The Veloxis Envarsus false expense reports concealed both the size of the hospitality and who received it. The separate Sunshine penalty addressed the company’s alleged failure to report physician payments to the Centers for Medicare & Medicaid Services.

Employees added names to dinner and event attendance lists to make the apparent cost per attendee smaller. They also omitted physicians who had attended to avoid reporting their benefits under the Sunshine Act. Adding a person and removing a person served different purposes: one diluted the expense on paper, while the other hid a recipient from the disclosure system.

Veloxis admitted that its reports to CMS relied on the falsified expense reports. As a result, it underreported or failed to report the true amounts transferred to physicians. The inaccurate internal record became the inaccurate public disclosure.

At the time of the announcement, the Department of Justice called the reporting penalty the largest Sunshine Act recovery since the law passed in 2010.

How Can You Find Out If Your Doctor Is Getting Kickbacks From Pharmaceutical Companies?

Open Payments identifies transfers that manufacturers report. Understanding a suspected kickback takes the connection between the payment, its purpose and the drug business it was intended to influence. Our whistleblower experts assess that connection with the person who knows the underlying arrangement.

The database contains payment records rather than prescription claims. Some important payment channels, including discounts and rebates, sit outside its reporting requirements. Veloxis also shows how an omitted name on an expense report can conceal a physician’s benefit before the information reaches the public database.

The fuller account sits in the business records: who attended, what the company paid, what services it expected and what it received. In this case, the company admitted changing those records to conceal kickbacks. The reporting system depended on information the payer itself had falsified.

The Civil Settlement and the Changes Inside Veloxis

Veloxis entered a five-year Corporate Integrity Agreement with the Department of Health and Human Services’ Office of Inspector General. It requires a compliance program addressing kickback risks in financial arrangements and an independent compliance expert’s review of the program’s effectiveness.

A program that approves consulting contracts but never checks the consulting misses the central fact Veloxis admitted. So does a disclosure process that accepts an altered attendance list as the account of who benefited.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The Veloxis settlement included claims brought through a qui tam case by a corporate whistleblower.

For pharmaceutical whistleblowers, the practical value of this case is the connection between a commercial arrangement and the records describing it. Consulting work that never happened, payments for unverified pharmacy services and edited attendance lists each exposed a different part of the same effort to sell Envarsus.

You Know What the Payment Bought

If you handled consulting engagements, pharmacy accounts or expense reporting and saw payments buying drug business, speak to one of our whistleblower experts about what those payments bought. We work beside you to build your strongest pharmaceutical kickback case and bring in pharmaceutical kickback whistleblower lawyers who understand manufacturer and pharmacy arrangements.